<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Thirty-eight atherosclerotic patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> disorders of the cerebral circulation (CDCC) received 300 mg of complamin by intravenous drip </plain></SENT>
<SENT sid="1" pm="."><plain>The clinical signs of vasodilation were noted at 5-15 min after the initiation of infusion whereas following it the findings observed included a significant reduction in the kinetic parameters of the myocardium and globular blood volume, an elevation in the peripheral vascular resistance and tone of the cerebral hemisphere vessels, a decrease in the pulse vascular resistance and tone of the cerebral hemisphere vessels, a decrease in the pulse blood-filling of the left carotid bed and deterioration of intracerebral venous <z:mpath ids='MPATH_107'>congestion</z:mpath> </plain></SENT>
<SENT sid="2" pm="."><plain>Complamin is recommended for use to improve the rheological properties of the blood and microcirculation in patients with CDCC with elevated or <z:mpath ids='MPATH_458'>normal</z:mpath> myocardial contractility </plain></SENT>
<SENT sid="3" pm="."><plain>Its application should be avoided in patients with low cardiac output and <z:hpo ids='HP_0001635'>heart failure</z:hpo>, in cases of labile arterial pressure and vascular <z:hpo ids='HP_0001332'>dystonia</z:hpo> with marked pulse variations in the cerebral vessels and also when the blood return to the cerebral veins is impeded </plain></SENT>
</text></document>